Eli Lilly Completes $1.5 Billion Acquisition of Prevail Therapeutics

January 25, 2021
BioPharm International Editors

Through the acquisition, Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets.

Eli Lilly and Company announced on Jan. 22, 2021 that it has completed its $1.5 billion acquisition of Prevail Therapeutics, a US-based gene therapy company.

Through the acquisition, Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets that include PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease, PR006 for patients with frontotemporal dementia with GRN mutations, PR004 for patients with specific synucleinopathies, and possible gene therapies targeted at Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative disorders, Lilly said in a Dec. 15, 2020 company press release. With Prevail’s pipeline, Lilly will work to create a new gene therapy program.

"We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher, and dementia," said Mark Mintun, MD, vice president of pain and neurodegeneration research at Lilly, in a Jan. 22, 2021 company press release.

Source: Eli Lilly

https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-prevail-therapeutics

https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-prevail-therapeutics